Pernix Therapeutics Holdings Inc were incorporated in Maryland in November 1996. The Company is a specialty pharmaceutical company that sells, markets, manufactures and develops a number of branded and generic pharmaceutical products primarily indicated for sleep, bacterial infections and cough and cold conditions. The Company branded products includes CEDAX, an antibiotic for middle ear infections, and a family of prescription treatments for cough and cold. The Company also market SILENOR (doxepin), which is approved for the treatment of insomnia characterized by difficulty with sleep maintenance and is not a controlled substance. The Company also currently promotes Omeclamox-Pak through a License and Supply Agreement with GastroEntero-Logic, LLC; as entered into a promotion agreement with Cumberland Pharmaceuticals pursuant to which Cumberland began promoting Omeclamox-Pak to gastroenterologists. The Company also entered into an Exclusive License Agreement with Osmotica Pharmaceutical Corp. to promote its desvenlafaxine product, Khedezla Extended-Release Tablets, 50 and 100 mg. It sells its generic products in the areas of cough and cold, pain, vitamins, dermatology, antibiotics and gastroenterology through its wholly-owned subsidiaries. The Companys branded product portfolio includes; SILENOR; KHEDEZLA; CEDAX; ZUTRIPRO; REZIRA; VITUZ; and OMECLAMOX-PAK. The products of the Company face competition from a variety of similar therapeutic branded and generic products. The Companys product candidates and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the DEA and other regulatory agencies in the United States and by comparable European authorities.